316 related articles for article (PubMed ID: 30360669)
1. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
Brakoulias V; Stockings E
Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
3. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
4. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
5. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
[TBL] [Abstract][Full Text] [Related]
6. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
[TBL] [Abstract][Full Text] [Related]
7. Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake Inhibitors.
Gautam M
J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):369-377. PubMed ID: 37335203
[TBL] [Abstract][Full Text] [Related]
8. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
Wheaton MG; Rosenfield D; Foa EB; Simpson HB
J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
Masi G; Pfanner C; Brovedani P
J Psychiatr Res; 2013 Aug; 47(8):1007-12. PubMed ID: 23664673
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
Pessina E; Albert U; Bogetto F; Maina G
Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
[TBL] [Abstract][Full Text] [Related]
17. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
[TBL] [Abstract][Full Text] [Related]
18. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
[TBL] [Abstract][Full Text] [Related]
19. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
20. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
